膵癌に対する細胞療法(MUC1-CTL療法,MUC1-DC療法)(<特集>細胞治療とアフェレシス)

概要

論文の詳細を見る
MUC1 is a tumor-associated antigen that is overexpressed in invasive ductal carcinomas of the pancreas (PC). MUC1-specific cytotoxic T lymphocytes (CTLs) recognize MUC1 molecules in a HLA-unrestricted manner. We performed adoptive immunotherapy (AIT) in patients with PC with CTLs stimulated by the MUC1-expressing human PC cell line YPK-1. We treated 14 patients with unresectable PC and 20 patients with resectable PC postsurgically. Median survival time was 5.6 months for patients with unresectable PC. None of 5 patients without liver metastasis showed hepatic recurrence. 1-, 2-, and 3-year survival rates after curative surgery for 18 patients with resectable PC were 82.6, 31.8, and 18.1%, respectively. Liver metastasis was found in only 1 patient and no side effects of AIT were observed. AIT with stimulated CTLs significantly suppressed postsurgical hepatic recurrence of PC. To improve the outcome for patients with unresectable PC, we induced MUC1 peptide pulsed dendritic cell and MUC1 specific cytotoxic T cell combined therapy. We treated 11 unresectable PC patients, and we could confirm stable disease for 2 patients and complete remission for 1 patient. In conclusion, MUC1 specific cytotoxic T cell therapy and MUC1 peptide pulsed dendritic cell therapy may be useful for PC patients.
日本アフェレシス学会の論文
2007-05-31